Invited Speakers
Memorial Lecture
-
ML01
Regulation of PCNA for Proper DNA Replication and Suppression of Genomic Instability
Prof. Kyungjae Myung
UNIST / Institute for Basic Science, Korea
CV
-
ML02
Biological Heterogeneity of AML: Implications for Prognosis and Treatment
Prof. Clara Bloomfield
The Ohio State University, USA
CV
-
ML03
Approaching Survival of the General Population: The Results of CML Study IV in the Global Context
Prof. Rüdiger Hehlmann
Heidelberg University, Germany
CV
-
ML04
New Models of Human Leukemia
Dr. Connie Eaves
British Columbia Cancer part of Provincial Health Services Authority, Canada
CV
-
ML05
Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes
Prof. David G. Maloney
Fred Hutchinson Cancer Research Center, USA
CV
-
ML06
Leukemia Stem Cell and Bone Marrow Microenvironment Interactions
Prof. Ravi Bhatia
The University of Alabama at Birmingham, USA
CV
-
ML07
Understanding Evolution and Outcomes in Myeloproliferative Neoplasms
Dr. Jyoti Nangalia
Wellcome Sanger Institute, UK
CV
Keynote Speech
-
KS
Treatment of Adult T-cell Leukemia (ATL) and a Novel Epigenetic Drug against ATL
Prof. Toshiki Watanabe
The University of Tokyo, Japan
CV
Session 1: Virus Associated Hematologic Malignancies
-
SY01-1
HTLV-1/BLV Genomic Approaches to Understanding Adult T-cell Leukemia
Dr. Anne Van den Broeke
Jules Bordet Institute - ULB, Belgium
CV
-
SY01-2
Hydroa-vacciniforme-like Lymphoproliferative Disease: A Cutaneous Form of CAEBV
Prof. Young-Hyeh Ko
Sungkyunkwan University, Korea
CV
-
SY01-3
Can We Cure Adult T Cell Leukemia/Lymphoma?
Prof. Ali Bazarbachi
American University of Beirut-Medical Center, Lebanon
CV
Session 2: Myelodysplastic Syndromes
-
SY02-1
DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation
Prof. Myunggon Ko
Ulsan National Institute of Science and Technology, Korea
CV
-
SY02-2
Iron Toxicity in MDS
Prof. Daniela Cilloni
University of Torino, Italy
CV
-
SY02-3
DDX41 Mutations in Myelodysplastic Syndrome
Prof. Je-Hwan Lee
University of Ulsan, Korea
CV
-
SY02-4
Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy
Prof. Michael Lübbert
University of Freiburg Medical Center, Germany
CV
Luncheon Symposium 1 [Sponsored by Bristol-Myers Squibb]
-
LS01
Recent Treatment Advances for Patients with Chronic Myeloid Leukaemia (CML): Insights from the UK SPIRIT2 Trial
Prof. Richard Clark
University of Liverpool, UK
CV
Session 3: Acute Myeloid Leukemia
-
SY03-1
The Rapidly Evolving Field of AML
Prof. Gert Ossenkoppele
Amsterdam University Medical Center, location VUMC, The Netherlands
CV
-
SY03-2
Curative Treatment Options for Older Patients with AML
Prof. Hervé Dombret
Saint-Louis Institute for Research/ University of Paris, France
CV
-
SY03-3
Development of a Novel FLT3 Inhibitor
Prof. Hitoshi Kiyoi
Nagoya University, Japan
CV
-
SY03-4
Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML
Prof. Jeffrey Tyner
Oregon Health & Science University, USA
CV
Session 4: Chronic Myeloid Leukemia
-
SY04-1
Next Generation Sequencing for Chronic Myeloid Leukemia
Prof. Susan Branford
Centre for Cancer Biology, SA Pathology, Australia
CV
-
SY04-2
New Horizon for CML Therapy: Treatment Discontinuation (TFR)
Prof. Giuseppe Saglio
University of Turin, Italy
CV
-
SY04-3
Novel Agents for Chronic Myeloid Leukemia
Prof. Michael Mauro
Memorial Sloan Kettering Cancer Center, USA
CV
-
SY04-4
Allogeneic Stem Cell Transplantation in CML
Prof. Eduardo Olavarria
Imperial College London, UK
CV
Session 5: Multiple Myeloma
-
SY05-1
Clinical and Biological Significance of RNA Editing Defect in Myeloma
Prof. Wee Joo Chng
National University Health System, Singapore
CV
-
SY05-2
Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma Patients
Prof. Roberto Mina
University of Torino, Italy
CV
-
SY05-3
Minimal Residual Disease: A Pitfall between Next-Generation Flow and Next-Generation Sequencing Analyses in Myeloma
Prof. Dong Soon Lee
Seoul National University, Korea
CV
Session 6: Acute Lymphoblastic Leukemia
-
SY06-1
Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model
Prof. Itaru Kato
Kyoto University, Japan
CV
-
SY06-2
Targeting Adhesion Molecules in B-ALL
Prof. Yong-Mi Kim
University of Southern California, USA
CV
-
SY06-3
Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia
Prof. Dieter Hoelzer
Onkologikum Frankfurt, Germany
CV
-
SY06-4
Ph+ ALL in Adults Evolving Place for TKIs, Chemotherapy, Immunotherapy and Transplantation
Dr. Françoise Huguet
University Institute of Cancer, France
CV
Luncheon Symposium 2 [Sponsored by Novartis]
-
LS02
Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CML
Prof. Yosuke Minami
National Cancer Center Hospital East, Japan
CV
Session 7: Molecular Mechanisms
-
SY07-1
Understanding and Targeting the Stem Cell Origins of MDS and AML
Prof. Ulrich Steidl
Albert Einstein College of Medicine - Montefiore Medical Center, USA
CV
-
SY07-2
Genetics and Mechanisms of Chemotherapy Resistance in Relapse Acute Lymphoblastic Leukemia
Prof. Adolfo Ferrando
Columbia University, USA
CV
-
SY07-3
Clonal Origin of Cancer
Prof. Seishi Ogawa
Kyoto University, Japan
CV
-
SY07-4
Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution
Prof. Semin Lee
Ulsan National Institute of Science and Technology, Korea
CV
Session 8: Lymphoma/ Chronic Lymphocytic Leukemia
-
SY08-1
Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia
Prof. Gianluca Gaidano
University of Eastern Piedmont, Italy
CV
-
SY08-2
CLL/SLL: from Genetics to the Clinic
Prof. Wei Xu
Jiangsu Province Hospital, China
CV
-
SY08-3
Management of NK/T-cell Lymphoid Malignancy
Prof. Seok Jin Kim
Samsung Medical Center, Korea
CV
-
SY08-4
Targeting Chronic Lymphocytic Leukemia in the Front Line
Prof. Richard A. Larson
The University of Chicago, USA
CV
Session 9: Myeloproliferative Neoplasms
-
SY09-1
2020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative Neoplasms
Prof. Jan Jacques Michiels
Goodheart Institute and Foundation, The Netherlands
CV
-
SY09-2
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis
Prof. Ki-Seong Eom
The Catholic University of Korea, Korea
CV
-
SY09-3
Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia
Prof. Hideki Muramatsu
Nagoya University, Japan
CV
Session 10: Leukemia Researches in Asian Sector
-
SY10-1
Study of Hematopoiesis Using Zebrafish Model System
Dr. Yoonsung Lee
UNIST / Institute for Basic Science, Korea
CV
-
SY10-2
Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells
Dr. Kazuhito Naka
Hiroshima University, Japan
CV
-
SY10-3
Progress of CAR-T Cell Therapy for Hematological Malignancies in China
Prof. Xiaojun Huang
Peking University People's Hospital, China
CV
-
SY10-4
CAR T Cells in Hematologic Malignancies: What’s Next?
Prof. Jae Park
Memorial Sloan Kettering Cancer Center, USA
CV